Background: Antiviral suppressive therapy of genital herpes is often initiated based on the
established pattern of recurrences in an individual. Because most persons with first episode …

Objectives: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration
and severity of genital herpes recurrences and to measure the frequency of viral shedding …

Objective. Genital herpes (GH) recurrences and viral shedding are more frequent in the first
year after initial HSV‐2 infection. The objective of this study was to provide the first …

OBJECTIVE To determine the efficacy of daily suppressive therapy with a 1-g dose of
valacyclovir in reducing total (clinical and subclinical) herpes simplex virus 2 (HSV-2) …

Background: A substantial number of HSV-2 seropositive individuals lack a history of
clinically recognized genital herpes. These individuals can transmit disease during periods …

Objective: To document the frequency of genital herpes recurrences in men and women with
histories of recurrent genital herpes during 1 year of continuous, suppressive therapy with …

Study Design: This was an international, multicenter, randomized, double-blind clinical trial
comparing 10-day regimens of valaciclovir (1000 mg, twice daily) and acyclovir (200 mg, 5 …

A randomized, double-blind study of valaciclovir for suppression of recurrent genital herpes
was conducted among 1479 immunocompetent patients. Patients were randomized to …

Background: Suppressive therapy has not been studied during the first year after acquisition
of genital herpes, the time of maximum frequency of reactivation, potential for transmission …

Three randomized controlled trials of valacyclovir for the management of recurrences of
genital herpes in HIV-infected persons were conducted between 1991 and 2002. One study …